Development of cancer prevention based on the molecular mechanism against malignant mesothelioma.

• Project/Area Number: 21390192
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Hygiene
• Research Institution: Kyoto Prefectural University of Medicine
• Principal Investigator: SOWA Yoshihiro 京都府立医科大学, 医学研究科, 准教授 (70315935)
• Co-Investigator(Kenkyū-buntansha): TOMOSUGI Mano (HORINKA Mano) 京都府立医科大学, 医学研究科, 助教 (80512037)
• Project Period (FY): 2009 – 2012
• Project Status: Completed (Fiscal Year 2012)
• Budget Amount: ¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000); Fiscal Year 2012: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000); Fiscal Year 2011: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000); Fiscal Year 2010: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000); Fiscal Year 2009: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
• Keywords: 悪性中皮腫 / DNA メチル化 / microRNA / HDAC 阻害剤 / DNAメチル化 / HDAC阻害剤 / Reactive oxygen species (ROS) / ミトコンドリア / Reactive oxygen species(ROS) / グルタチオン / アポトーシス

Research Abstract

In malignant mesothelioma cells, miR-34b/c, which is known as a tumor suppressive microRNA, is suppressed by DNA methylation. Since the combination treatment of DNA methyltransferase inhibitor and histone deacetylase (HDAC) inhibitor abrogated the DNA methylation, we treated malignant mesothelioma cells with the combination. As a result, the combination induced growth arrest, apoptosis and the upregulation of miR-34b/c. These results raise a possibility that the combination treatment of DNA methyltransferase inhibitor and HDAC inhibitor might be useful for the treatment and prevention against malignant mesothelioma.

Research Products

• [Journal Article] Histone deacetylase inhibitors and 15-deoxy-Δ^<12,14>-prostaglandin J_2 synergistically induce apoptosis. (2010)
  • Author(s): Koyama M, et al.
  • Journal Title: Clinical Cancer Research Volume: 16(8) Pages: 2320-2332
  • Peer Reviewed
• [Journal Article] HDAC阻害剤の開発状況 (2010)
  • Author(s): 曽和義広
  • Journal Title: 癌と化学療法 Volume: 37(9) Pages: 1665-1668
• [Presentation] HDAC阻害剤と15-deoxy-Δ^<12,14>-prostaglandin J_2の併用療法は相乗的にアポトーシスを引き起こす (2010)
  • Author(s): 小山真, 他
  • Organizer: 日本がん分子標的治療学会
  • Place of Presentation: 東京
  • Year and Date: 2010-07-08
• [Presentation] Histone deacetylase inhibitors and 15-deoxy-Δ^<12,14>-prostaglandin J_2 synergistically induce apoptosis. (2010)
  • Author(s): Koyama M, et al.
  • Organizer: American Association for Cancer Research
  • Place of Presentation: Washington D.C., U.S.A
  • Year and Date: 2010-04-21
• [Remarks]
  • URL: http://www.f.kpu-m.ac.jp/k/pubmed/
• [Remarks]
  • URL: http://www.f.kpu-m.ac.jp/k/pubmed/
• [Remarks]
  • URL: http://www.f.kpu-m.ac.jp/k/pubmed/
• [Remarks]
  • URL: http://www.f.kpu-m.ac.jp/k/pubmed/